CLOs on the Move

Medvantx

www.medvantx.com

 
Medvantx Pharmacy Services helps pharmaceutical brands do more than just survive in an ever-changing marketplace - we help them thrive in it. Medvantx provides powerful and personalized support to healthcare partners (HCPs) and their patients. We service the specialty needs of pharmaceutical manufacturers by offering patient assistance programs and providing efficient intake solutions, nationwide dispense and fulfillment services, quality aftercare through counseling and customer service, safe and secure data handling, dependable inventory management and logistics, and insightful reporting and accounting. Serving more than 50 pharmaceutical manufacturers and managing more than $7.5 billion B of prescriptions annually, Medvantx has been redefining ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.medvantx.com
  • 4655 Executive Drive Suite 230
    San Diego, CA USA 92121
  • Phone: 866.744.0621

Executives

Name Title Contact Details
Darlene Mitchell
Chief Compliance Officer Profile

Similar Companies

Porzio Life Sciences

Regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations.

FamilyofKidz

Therapeutic and Educational Services Provider

Gala Design Inc

Gala Design Inc is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apotex

Apotex is the largest Canadian owned pharmaceutical company, and the largest producer of generic medicines in the country. Founded in 1974, Apotex has steadily grown to employ over 10,000 people around the world, focused on research, development, manufacturing and distribution.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.